Biotechnology
HOYA Group PENTAX Medical Cleared CE Mark for DISCOVERY(TM), an AI Assisted Polyp Detector
TOKYO, Dec. 16, 2019 /PRNewswire/ -- PENTAX Medical, a division of the HOYA Group, announced that it has cleared CE mark for DISCOVERY™, an innovative Artificial Intelligence (AI) assisted polyp detector designed to support endoscopists in finding potential polyps during a colorectal examination....
2019-12-16 16:00
1892
Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS
TAIPEI and SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Senhwa Biosciences Inc. (TPEx: 6492), a clinical stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced positive results from its Phase 1 trial of CX-5461. C...
2019-12-13 04:00
2413
Drug Manufacturers Eye Analytical Instrumentation to Reduce Operating Costs
SANTA CLARA, California, Dec. 12, 2019 /PRNewswire/ -- The total analytical instrumentation market in pharmaceuticals, biopharmaceuticals, and nutraceuticals generated revenues of $3.05 billion in 2018 and is expected to grow at aCAGR of 7.0% to touch $4.91 billion in 2025. Pharmaceuticals were t...
2019-12-12 23:11
1155
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's Therapeutic Goods ...
2019-12-12 14:47
3324
Biocon Biologics Symposium on '100 Years of Insulin - Delivering on Universal Access & Equitable Care' Resonates Well With Leading KOLs at IDF Congress 2019
BENGALURU, India, Dec. 12, 2019 /PRNewswire/ -- Biocon Biologics, a fully integrated 'pure play' global biosimilars organisation, brought together Key Opinion Leaders (KOLs), including physicians, scientists, healthcare professionals, government representatives, policy makers, and IDF members, at...
2019-12-12 09:00
1641
Human Microbiome Market to Reach $6.08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics
SANTA CLARA, California, Dec. 11, 2019 /PRNewswire/ -- There has been a surge in industry-academia collaborations in thehuman microbiome therapeutics space. The partnerships betweenpharma/biotech companies and academic institutes are bringing together the research expertise of educational organiz...
2019-12-11 23:55
942
AGC Biologics Expands Plasmid DNA Offering
SEATTLE, Dec. 11, 2019 /PRNewswire/ -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from itsHeidelberg site in Germany. With the demand for pDNA growing rap...
2019-12-11 09:06
2170
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...
2019-12-11 08:41
6486
Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"
SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results ...
2019-12-11 08:00
12318
Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies
SUZHOU, China and SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd ("Gracell"), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American...
2019-12-09 22:00
1392
Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours
* First in-human Clinical Phase I study of intratumoural tigilanol tiglate (EBC-46) has been published in The Lancet's EBioMedicine journal; * An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans; * Promising...
2019-12-09 21:01
1452
BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors
HANGZHOU, China, Dec. 9, 2019 /PRNewswire/ -- BJ Bioscience Inc. (the
'company') today announced that the first patient was successfully dosed on
December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001
program at NEXT ONCOLOGY inSan Antonio, Texas.
2019-12-09 21:00
1551
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody
SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company committed to discovering and developing a combined platform of Chimeric Antigen Receptor T (CAR-T) cell therapies and monoclonal antibodies for cancer, today announced that one of its leading d...
2019-12-09 18:00
3360
PRC NHC Issues New Policy on Cord Blood Banks, Implementation Rules To Be Provided
HONG KONG, Dec. 6, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported thatChina's National Health Commission ("NHC") ...
2019-12-06 20:00
15362
Global Cord Blood Corporation Announces Results of 2019 Annual General Meeting
HONG KONG, Dec. 5, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2019 Annual Gene...
2019-12-05 21:30
13408
Announcement of collaborative research agreement with National Cancer Center on analysis of gut bacteria related to cancer
TOKYO, Dec. 5, 2019 /PRNewswire/ -- bitBiome, Inc. (Representative Director: Yoshihito Daimon, "bitBiome") and National Cancer Center of Japan (President: Hitoshi Nakagama, Chuo-ku, Tokyo, "NCC") have signed a collaborative research agreement on the analysis of gut bacteria related to cancer onNo...
2019-12-05 15:27
836
Hummingbird Bioscience Raises US$19 Million in Series B Financing
SINGAPORE, Dec. 5, 2019 /PRNewswire/ -- Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrough precision antibody therapeutics for difficult-to-treat conditions, today announced that it has raisedUS$19 million in a Series B finan...
2019-12-05 10:00
1874
Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine
Newly updated and expanded NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic clarify who should be tested for cancer-causing genetic mutations Experts caution about risks of direct-to-consumer genetic testing and stress the importance of genetic counselin...
2019-12-04 22:01
999
PathogenDx Lauded by Frost & Sullivan for Its Game-changing DNA-based Multiplex Microarray Technology
PathogenDx's breakthrough technology shifts the pathogen detection paradigm from microbial to molecular testing through its microarray assays, namely Detect X, EnviroX, and QuantX SANTA CLARA, California, Dec. 3, 2019 /PRNewswire/ -- Based on its recent analysis of the global microbial DNA testin...
2019-12-03 22:00
1402
VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia
AUSTIN, Texas, Dec. 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its latest proof of concept study. A single pre-clinical Nu.Q™ assay utilizing a basic microtiter plate platform detected 80% of newly diagnosed Non-Hodgkins Lymphoma ("N...
2019-12-03 21:30
11800
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 302 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8680
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5513
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4990
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4738
